Physician profile
Omar Ali
NPI 1760665863
$13,074.32
in general payments reported to CMS, 2019-2025
46 companies · $972 in 2025
The $972 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $717 · 2021: $1,825 · 2022: $3,080 · 2023: $2,160 · 2024: $2,015 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Travel and Lodging: $1,117 · Long Term Medical Supply Or Device Loan: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.64 |
| Travel and Lodging | $1,117.13 |
| Long Term Medical Supply Or Device Loan | $281.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,251.98 | 2019-2025 | Watchman Access System, Peripheral Rotalink Plus, Lux-Dx Insertable Cardiac Monitor |
| Edwards Lifesciences Corporation | $1,611.02 | 2019-2024 | Pascal |
| Abbott Laboratories | $1,215.19 | 2019-2025 | Portico, Triclip, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,092.49 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $849.17 | 2019-2023 | Xarelto |
| Cardiovascular Systems INC. | $515.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $497.61 | 2019-2023 | |
| Artivion, INC. | $426.68 | 2021 | |
| Alnylam Pharmaceuticals INC. | $354.65 | 2022-2024 | Amvuttra |
| Amgen INC. | $346.88 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $317.95 | 2022-2023 | Verquvo |
| Kestra Medical Technology Services, INC. | $246.77 | 2022-2025 | Assure Wcd |
| Pfizer INC. | $242.46 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $241.04 | 2019-2022 | |
| Biotissue Holdings INC. | $212.48 | 2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $177.96 | 2022-2025 | Flexitouch Plus, Nimbl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.91 | 2021-2025 | Jardiance |
| Biosense Webster, INC. | $145.83 | 2025 | Carto 3 |
| Novo Nordisk INC | $110.23 | 2021-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $107.00 | 2019-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $98.10 | 2024-2025 | Eylea Hd, Eylea |
| Lexicon Pharmaceuticals, INC. | $76.79 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $76.10 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $68.85 | 2022-2023 | |
| Convatec INC. | $54.97 | 2023 | |
| Preventice Services, LLC | $51.91 | 2019-2021 | |
| Stryker Corporation | $51.51 | 2025 | Artix Mt |
| Cardiva Medical, INC. | $43.86 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Chiesi USA, INC. | $40.24 | 2020-2022 | |
| Astellas Pharma US INC | $40.12 | 2019-2021 | |
| Teleflex LLC | $37.10 | 2023 | Manta, Guideliner |
| Abiomed | $33.54 | 2022-2023 | Impella |
| Penumbra, INC. | $31.86 | 2020-2025 | Penumbra System |
| Livanova USA, INC. | $24.31 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.19 | 2025 | Edarbyclor |
| Ekos Corporation | $23.83 | 2019 | |
| Medtronic Vascular, INC. | $20.72 | 2020 | |
| Medicomp INC | $18.10 | 2023 | Telepatch Cardiac Monitor |
| Amarin Pharma, INC. | $17.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.28 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $16.00 | 2025 | Rhythm Express |
| Impulse Dynamics (USA) INC. | $15.03 | 2023 | Optimizer |
| Bsn Medical INC | $15.00 | 2022 | |
| Biotronik INC. | $14.29 | 2023 | Biomonitor |
| Medtronic, INC. | $14.14 | 2022 | |
| Elutia, INC. | $13.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.